Pharmaceutical logistics has traditionally been based on stability. Routes were well-established, volumes could be forecast with confidence and resilience was built through inventory and time.
When disruption occurred, it was usually absorbed by stock buffers or alternative distribution routes.
Advanced therapies are changing those assumptions. Cell and gene therapies, personalised medicines and temperature-sensitive biologics operate within much tighter tolerances.
Shipments are often smaller, delivery windows are narrower and, in some cases, each consignment is intended for a single patient.
The scope for delay or deviation is limited and the impact of failure is more significant.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.